Psychopharmacological treatment of non-comorbid and comorbid pervasive developmental disorder and pediatric bipolar disorder

Minerva Pediatrica

Volumn 60, Issue 1, 2008, Pages 87-101

  Hamrin, V ^a,d   Mcdonnell, M A ^b   Moffett, J ^c   Durso, S ^a  

^a YALE UNIVERSITY   (United States)

^b STEP UP for Kids Inc   (United States)

^c MCLEAN HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Adolescent; Bipolar disorder, therapy; Child; Child development disorders, pervasive, therapy; Comorbidity

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; DESIPRAMINE; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXYCARBAMAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AUTISM; BIPOLAR DISORDER; BLURRED VISION; COMORBIDITY; DIZZINESS; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERACTIVITY; HYPOMANIA; LOW DRUG DOSE; MANIA; MEMORY DISORDER; MONOTHERAPY; NAUSEA; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME;

ADOLESCENT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; TREATMENT OUTCOME;

EID: 42049117607     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Kurita H, Osada H, Shimizu K, Tachimori H. Bipolar disorders in mentally retarded persons with pervasive developmental disorders. J Dev Phys Disabil 2004;16:377-89.
2. Towbin KE, Pradella A, Gorrindo T, Pine DS, Leibenluft E. Autism Spectrum Traits in Children with Mood and Anxiety Disorders. J Child Adolesc Psychopharmacol 2005;15:452-64.
3. Stahlberg O, Soderstrom H, Rastam M, Gillberg C. Bipolar disorder, schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. J Neural Transm 2004;111:891-902.
4. Wozniak J, Biederman J, Farone S, Frazier J, Kim J, Millstein R et al. Mania in children with pervasive developmental disorder revisited. J Am Acad Child Adolesc Psychiatry 1997;36:1552-9.
5. Findling R. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. J Clin Psychiatry 2005;66:26-31.
6. Scahill L, Martin A. Psychopharmacological treatment of children and adults with autism. In: Volkmar FR, Klin A, Paul R, editors. Handbook of Autism. New York: Wiley Publishers; 2006.
7. Frankhouser M, Karumanchi V, German M, Yates M, Karumanchi S. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
8. Jaselskis C, Cook E, Fletcher K, Leventhal B. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;1:322-7.
9. Posey D, Puntney J, Sasher T, Ken T, McDougle C. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14:233-41.
10. Pavuluri M, Henry D, Devineni B, Carbray J, Naylor M, Janicak P. A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2004;43:859-67.
11. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 1992;149:363-6.
12. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-7.
13. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979;36:555-9.
14. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-11.
15. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-84.
16. Cook E, Rowlett R, Jaselskis C. Leventhal B. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-45.
17. DeLong GR, Ritch C, Burch S. Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002;44:652-9.
18. Fatemi S, Realmuto G, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longi-tudinal open trial. J Autism and Dev Disord 1998;28:303-7.
19. Hollander E, Phillips A, Chaplin W, Zafursky K, Novotny S, Wasserman S. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-9.
20. Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Autism Dev Disord 2003;33:77-85.
21. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-8.
22. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001;344:1279-85.
23. Steingard R, Zimnitzky B, Demaso D, Bauman M, Bucci J. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997;7:9-15.
24. Posey D, Guenin K, Kohn A, Swiezy N, McDougle C. A naturalistic open label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001;11:267-77.
25. Hamrin V, Scahill L. Selective serotonin reuptake inhibitors in children and adolescents with major depression: Current controversies and recommendations. Issues Ment Health Nurs 2005;26:433-50.
26. Wilens T, Biederman J, Kwon A, Chase R, Greenberg L, Mick E et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003;13:143-52.
27. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviours. JAMA 2004;292:338-43.
28. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescent with major depressive disorder. A propensity-adjusted retrospective cohort study. CNS Drugs 2004;18:1119-32.
29. Baumer FM, Howe M, Gallelli K, Simeonova D, Hallmayer J, Chang KD. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol Psychiatry 2006;48:458-66.
30. Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE Jr et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006;163:313-5.
31. Papolos DF. Switching, cycling, and antidepressant-induced effects on cycle frequency and course of illness in adult bipolar disorder: a brief review and commentary. J Child Adolesc Psychopharmacol 2003;13:165-71.
32. Kowatch R, Delbello M. Pharmacotherapy of children and adolescents with bipolar disorder. Psychiatr Clin North Am 2005;28:385-97.
33. Bschor T, Lweitza U, Sasse J, Adli M, Koberle U, Bauer M. Lithium augmentation in treatment resistant depression. Clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 2003;36:S230-23.
34. Manji H, Lenox K. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999;46:1328-51.
35. Patel N, Delbello M, Bryan H, Adler C, Kowatch R, Stanford K et al. Open label lithium for the treatment of bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45:289-97.
36. Kowatch R, Suppes T, Carmody T, Bucci J, Hume J, Kromelis M et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000;39:713-20.
37. Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152-62.
38. Davanzo P, Gunderson B, Belin T, Mintz J, Pataki C, Ott D et al. Mood stabilizers in hospitalized children with bipolar disorder: A retrospective chart review. Psychiatry Clin Neurosci 2003;57:504-13.
39. Wagner K, Weller E, Carlson G, Sachs G, Biederman J, Frazier J et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2002;41:1224-30.
40. Singh V, Muzina DJ, Calabrese JR. Anticonvulsants in bipolar disorder. Psychiatr Clin North America 2005;28:301-23.
41. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62:530-4.
42. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalporex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006;9:209-13.
43. Saxena K, Howe M, Simeonova D, Steiner H, Change K. Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. J Child Adolesc Psychopharmacol 2006;16:252-9.
44. MacMillan C, Korndorfer S, Rao S, Fleisher C, Mezzacappa E, Gonzalez A et al. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J Psychiatr Pract 2006;12:214-22.
45. Hellings JA, Wechbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:682-92.
46. Aman M, Singh N. Aberrant behavior checklist. New York: Slosson Educational Publications, Inc.;1994.
47. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolescent Psychiatry 1998;37:171-8.
48. Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 2006;59:1061-4.
49. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006;163:1179-86.
50. Delbello M, Findling R, Kushner S, Wang D, Olson W, Capece J et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad of Child Adolesc Psychiatry 2005;44:539-47.
51. Tramontina S, Zeni C, Pheula G, Rohde L. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: An open clinical trial. J Child Adolesc Psychopharmacol 2007;17:129-34.
52. Barzman D, DelBello M, Kowatch R, Warner J, Rofey D, Stanford K et al. Adjunctive opiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005;15:931-7.
53. Wasserman S, Iyengar R, ChaplinW, Watner D, Waldoks S, Shulamit E. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006;21:363-7.
54. Carandang C, Maxwell D, Robbins D, Oesterheld J. Lamotrigine in adolescent mood disorders. J Am Acad Child Adolesc Psychiatry 2003;42:750-1.
55. Belsito K, Law P, Kirk K, Landra R, Simmerman A. Lamotrigine therapy for autistic disorder: A randomized, double blind, placebo controlled trial. J Autism Dev Disord 2001;31:175-81.
56. Anderson L, Campbell M, Adams P, Small A, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-39.
57. Campbell M, Cohen IL, Small AM. Drugs in aggressive behavior. J Am Acad Child Adolesc Psychiatry 1982;21:107-17.
58. Mikkelsen E. Efficacy of neuroleptic medication in pervasive developmental disorders of childhood. Schizophr Bull 1982;8:320-32.
59. Frazier J, Meyer M, Biederman J, Wozniak J, Wilens T, Spencer T et al. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999;38:960-5.
60. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV. An open label study of risperidone in children with bipolar disorder. J Child Adolesc Psychopharmacol 2005;15:311-7.
61. Frazier J, Biederman J, Tohen M, Feldman P, Jacobs T, Toma V et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-50.
62. Beiderman J, Mick E, Hammerness P, Harpold T, Aleardi M, Doughtery M et al. Open label 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder for preschool-age children. Biol Psychiatry 2005;58:589-94.
63. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2004;14:405-11.
64. DelBello M, Kowatch R, Caleb A, Stanford K, Welge J, Barzman D et al. A double-blind randomized pilot study comparing quetiapine and divalproex sodium for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006;45:305-13.
65. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 2005;10:141-8.
66. Howland RH. Atypical antipsychotics: special formulations for acute agitation. J Psychosoc Nurs Ment Health Serv 2005;43:14-7.
67. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:372-94.
68. Kowatch R, Suppes T, Gilfillan SK. Clozapine treatment of children and adolescent with bipolar disorder and schizophrenia: a clinical case series. J Child Adolesc Psychopharmacol 1995;5:241-53.
69. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients' with acute mania. J Child Adoles Psychopharmacol 2002;12:93-9.
70. Schreier HA. Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 1998;8:49-59.
71. Soutullo CA, Sorter MT, Foster KD, McElroy SL, Keck PE. Olanzapine in the treatment of adolescent acute mania: a report of seven cases. J Affect Disord 1999;53:279-83.
72. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive de-velopmental disorders. J Am Acad Child Adolesc Psychiatry 2001;40:1206-14.
73. Masi G, Cosenza A, Mucci M, Brovedani PA. Three year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64:1039-47.
74. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:634-41.
75. McCracken J, McGough J, Shah B, Cronin P, Hong D, Aman M. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21.
76. Williams S, Scahill L, Viteillo B, Michael A, Eugene A, McDougle C. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry 2006;45:431-9.
77. McDougle C, Scahill L, Aman M, McCracken J, Tierney E, Davies M et al. Risperidone for the Core Symptom domains of Autism: results from the study by the Autism Network Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005;162:1142-8.
78. Hollander E, Wasserman S, Swanson E, Chaplin W, Schapiro M, Zagursky K et al. A double blind placebo controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541-8.
79. Chen NC, Bedair HS, McKay B, Bowers MB, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001;62:479-80.
80. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996;153:738.
81. Findling R, McNamara N, Stansbrey R, Gracious B, Whipkey R, Demeter M et al. Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. J Am Acad Child Adolesc Psychiatry 2006;45:142-8.
82. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-24.
83. Pavuluri M, Henry D, Carbray J, Sampson G, Naylor M, Janicak P. One-year open label trial of risperidone augmentation in lithium nonresponder youth with preschool - onset bipolar disorder. J Child Adolesc Psychopharmacol 2006;16:336-50.
84. Bertoldo M. Valproic acid and riperidone. J Am Acad Child Adolesc Psychiatry 2002;41:632.
85. Van Wattum P. Valproic acid and risperidone. J Am Acad Child Adolesc Psychiatry 2001;40:866-7.
86. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22.
87. Di Martino A, Melis G, Cianchetti C, Zuddas A. Meythylphenidate for pervasive developmental disorders: Safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J Child Adolesc Psychopharmacol 2004;14:207-18.
88. Handen B, Johnson C, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention deficit disorder. J Autism Dev Disord 2000;30:245-55.
89. Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995;25:283-94.
90. Aman M, Buican B, Arnold L. Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. J Child Adolesc Psychopharmacol 2003;13:29-40.
91. Pavuluri M, Henry D, Carbray J, Naylor M, Janicak P. Divalproex sodium for pediatric mixed mania: a 6-month prospective trial. Bipolar Disord 2005;7:266-73.
92. Scheffer R, Kowatch R, Carmody T, Rush A. Randomized, placebo controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005;162:58-64.
93. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol 2003;13:123-36.
94. Goldstein T, Birmaher B, Axelson D, Ryan N, Strober M, Gill M et al. History of suicide attempts in pediatric bipolar disorder: factors associated with increased risk. Bipolar Disord 2005;7:525-35.
95. Strober M, Schmidt-Lackner S, Freeman R, Bower S, Lampert C, DeAntonio M. Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up. J Am Acad Child Adolesc Psychiatry 1995;34:724-31.
96. Findling R, McNamara N, Youngstrom E, Stansbrey R, Gracious B, Reed M et al. A double blind 18 month trial of lithium versus divalproex maintenance treatment in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:409-17.